Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP), Amedisys (AMED) and Xoma (XOMA)
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Corbus Pharmaceuticals (CRBP)
LifeSci Capital analyst Dennis Kennedy maintained a Buy rating on Corbus Pharmaceuticals on July 1 and set a price target of $53.00. The company's shares closed last Thursday at $7.71, close to its 52-week low of $5.49.
According to TipRanks.com, Kennedy is ranked #3144 out of 9710 analysts.
Currently, the analyst consensus on Corbus Pharmaceuticals is a Strong Buy with an average price target of $43.14.
Amedisys (AMED)
In a report issued on June 30, Whit Mayo from Leerink Partners maintained a Hold rating on Amedisys, with a price target of $101.00. The company's shares closed last Thursday at $96.10.
According to TipRanks.com, Mayo is a 3-star analyst with an average return of 2.7% and a 49.4% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Ardent Health Partners, Inc., Clover Health Investments, and Pediatrix Medical Group.
Currently, the analyst consensus on Amedisys is a Hold with an average price target of $100.67.
Xoma (XOMA)
Leerink Partners analyst David Risinger maintained a Buy rating on Xoma on June 30. The company's shares closed last Thursday at $26.96.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of 8.5% and a 53.0% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Centessa Pharmaceuticals, and Vertex Pharmaceuticals.
Currently, the analyst consensus on Xoma is a Strong Buy with an average price target of $69.50.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Why Is UnitedHealth Stock Trading Higher Friday?
UnitedHealth Group Inc. (NYSE:UNH) shares climbed Friday after high-profile investors Michael Burry and Warren Buffett took positions in the insurance giant, offering some relief to a stock that has tumbled about 41% year-to-date. Warren Buffett's fund bought little more than 5 million shares, and Burry disclosed in 13F filings that he purchased call contracts against 350,000 shares of UnitedHealth. The holdings suggest Burry is betting on a sector turnaround, particularly as Medicare Advantage rates have exceeded expectations for 2026, and UnitedHealth's competitive positioning remains strong despite recent a U.S. Securities and Exchange Commission (SEC) filing on Thursday, Amedisys (NASDAQ:AMED) announced that UnitedHealth closed its home health and hospice provider acquisition. UnitedHealth agreed to divest more than 160 healthcare facilities as part of a proposed settlement with the U.S. Department of Justice (DOJ) to resolve antitrust concerns surrounding its $3.3 billion acquisition of Amedisys. The insurance giant reported second-quarter adjusted earnings of $4.08, down from $6.80 a year ago, missing the consensus of $4.95. Revenues increased 13% year over year to $111.62 billion, missing the consensus of $111.69 billion. UnitedHealth reestablished its fiscal year 2025 guidance, with adjusted earnings of at least $16 per share versus a consensus of $22.33 and sales guidance of $445.5 billion-$448 billion compared to the analyst estimate of $449.5 billion. In May, UnitedHealth suspended its 2025 performance outlook. In July, UnitedHealth engaged with the Department of Justice following reports of ongoing investigations into its Medicare program participation. The company said it has begun complying with the Department's formal criminal and civil requests. UnitedHealth says it has full confidence in its practices and is committed to working cooperatively with the Department throughout this process. Reuters reported that a cyberattack on UnitedHealth's technology unit last year affected 192.7 million people, citing the U.S. health department data. In January, the company had estimated the Change Healthcare breach impacted about 190 million people. Price Action: UNH stock is trading higher by 10.57% to $300.18 at last check Friday. Read Next:Photo by Ken Wolter via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? UNITEDHEALTH GROUP (UNH): Free Stock Analysis Report This article Why Is UnitedHealth Stock Trading Higher Friday? originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
15 hours ago
- Business Insider
M&A News: UnitedHealth (UNH) Closes $3.3B Amedisys Deal After Two-Year Antitrust Battle
Health insurer UnitedHealth (UNH) has finally completed its $3.3 billion acquisition of Amedisys, a home health and hospice provider, after two years of regulatory hurdles due to antitrust concerns. The deal, executed through UNH's Optum division, marks a major expansion of its footprint in home-based care. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Upon closing, Amedisys repaid $399.2 million to clear all outstanding debt. With the merger complete, Amedisys stock will no longer be traded on the Nasdaq. Each share of Amedisys common stock was converted into $101 in cash for shareholders. Regulatory Roadblocks and DOJ Settlement The merger faced intense scrutiny from the DOJ, which sued to block the deal in November 2024. Regulators feared the combination of Amedisys and UnitedHealth would stifle competition in home health and hospice markets. To resolve these issues, the companies entered a settlement with the DOJ. They have agreed to divest 164 facilities across 19 states to BrightSpring Health Services and The Pennant Group (PNTG). Further, Amedisys paid a $1.1 million civil penalty for false certification and agreed to antitrust compliance training. With Amedisys now part of UnitedHealth, the combined company is the largest hospice provider in the U.S., caring for over 465,000 patients a year. The deal supports Optum's plan to offer more connected and affordable care at home. Is UNH a Good Buy Right Now? Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 18 Buys, four Holds, and two Sells assigned in the last three months. At $312.65, the average UnitedHealth stock price target implies a 15.48% upside potential.
Business Insider
18 hours ago
- Business Insider
Twilio to replace Amedisys in S&P 400 at open on 8/19
Twilio (TWLO) will replace Amedisys(AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group (UNH) acquired Amedisys in a deal completed August 14. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
